



KENNY C. GUINN  
Governor

STATE OF NEVADA  
DEPARTMENT OF HUMAN RESOURCES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
NEVADA MEDICAID

MICHAEL J. WILLDEN  
Director

CHARLES DUARTE  
Administrator

## NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP"), Pharmacy and Therapeutics Committee will conduct a public meeting on January 27<sup>th</sup>, 2005 beginning at **1:00 p.m.** at the following location:

**Public Utilities Commission**  
**1150 E. William St. – Hearing Room B**  
**Carson City, Nevada**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-684-3715 or toll free at: 1-800-992-0900, ext. 43715 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

**Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.**

**Public comment may be limited to 5 minutes per person at the discretion of the Chairperson.**

### AGENDA

- I. Call to Order and Roll Call
- II. \*Review and Approval of October 28<sup>th</sup>, 2004, Meeting Minutes
- III. Report on Preferred Drug List Status - First Health Services – Approval Rate for Change Requests and Reasons for PDL Exception Requests
- IV. Report on Recent Actions Taken by Drug Use Review Board – First Health Services
  - A. Education Program – "Fiscal Pharmacology of the Atypical Antipsychotics: Getting the Biggest Bang Out of the Bucks"
  - B. Quantity Limitation Edits
  - C. Denials for ProDUR Severity Level One Messages
- V. Serotonin Agonists ("Triptans")
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VI. Re-review of Stimulants/ADHD Drug Class with Emphasis on Narcolepsy and Sleep Disorders
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented

1100 E. William Street, Suite 102, Carson City, Nevada 89701  
(775) 684-3600

- C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VII. Addition of Zofran® (ondansetron) to the Preferred Drug List (PDL)
  - A. Public Comment
  - B. Recommendation by First Health Services to Add Zofran® (ondansetron) to the Preferred Drug List:
    - Drug Class: Antiemetics, oral, 5-HT3s
    - Target Age Group: Patients less than 18 years old
  - C. \*Committee Discussion and Action
    - 1. Identify Exclusions/Exceptions
  - D. \*Committee Discussion and Approval of Zofran® for Inclusion in the PDL for Patients < 18 Years Old
- VIII. Review and Discussion of Current PDL Exception Processes - First Health Services
  - A. Unsuccessful Trial of a Preferred Drug
  - B. Continuity of Care Considerations
- IX. \*Committee Action to Revise Current PDL Exception Processes
  - A. Unsuccessful Trial of a Preferred Drug
  - B. Continuity of Care Considerations
- X. Committee Discussion of Possible Action to be Taken by Committee Regarding FDA Public Health Advisory Concerning the Use of Non-Steroidal Anti-inflammatory Drug Products (NSAIDS), Including Those Known as COX-2 Selective Agents
- XI. \*Committee Action Regarding FDA Public Health Advisory to Review Non-Steroidal Anti-inflammatory (NSAIDS) Drug Class, Including Those Known as COX-2 Selective Agents
- XII. Review of April 28, 2005, Meeting Location, Date, and Time
- XIII. Public Comment
- XIV. \*Adjournment

**\* Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

**Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([dhcfp@state.nv.us](mailto:dhcfp@state.nv.us)).**

**Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the action items will be mailed to you. They may also be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day**

**ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1000 E. William Street, Suite 102, Carson City, NV 89701.**

**All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.**

**Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.**